Boltz PBC

Based in the US, Boltz PBC specializes in AI-powered drug discovery, providing innovative solutions that streamline the drug development process through advanced technology and intelligent models. Founded in 2025 in Boston, US, Boltz PBC focuses on AI-driven drug discovery solutions. The company has successfully completed one funding round, securing USD 28. 00 mn in Seed funding on December 30, 2025, from investors including Amplify Partners, Andreessen Horowitz, Zetta Ventures, Factorial Capital and Obvious.

The founder's history and previous entrepreneurial ventures are not available. Boltz specializes in AI-powered drug discovery solutions, primarily through its Boltz Platform, which combines advanced AI models and intelligent agents to support the drug development process from hit identification to lead optimization. The platform allows scientists to define biological targets, perform extensive screenings, and integrate experimental data for refined results. Key offerings include the Boltz-1 co-folding model, Boltz-2 affinity prediction model, and BoltzGen binder design model, catering to biotech firms, pharmaceutical companies, and academic institutions across North America, Europe, and Asia.

Boltz generates revenue primarily through subscriptions and partnerships with research organizations and pharmaceutical companies, offering access to its AI-driven platform for drug discovery. Clients subscribe to tiered services that include proprietary models and expert support, establishing a steady revenue stream as the company expands its clientele within the life sciences sector. Following the recent Seed funding of USD 28. 00 mn raised on January 8, 2026, Boltz PBC plans to enhance its platform, integrate Pfizer historical data, and deploy AI-powered drug discovery agents.

The company aims to innovate new products and expand its market presence, targeting specific regions and sectors to leverage its technology effectively.